169 related articles for article (PubMed ID: 19258540)
1. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
[TBL] [Abstract][Full Text] [Related]
2. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
[TBL] [Abstract][Full Text] [Related]
3. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
[TBL] [Abstract][Full Text] [Related]
4. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
Thompson PA; Wertheim BC; Zell JA; Chen WP; McLaren CE; LaFleur BJ; Meyskens FL; Gerner EW
Gastroenterology; 2010 Sep; 139(3):797-805, 805.e1. PubMed ID: 20538001
[TBL] [Abstract][Full Text] [Related]
5. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas.
Raj KP; Zell JA; Rock CL; McLaren CE; Zoumas-Morse C; Gerner EW; Meyskens FL
Br J Cancer; 2013 Feb; 108(3):512-8. PubMed ID: 23340449
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms.
Sinicrope FA; Velamala PR; Song LMWK; Viggiano TR; Bruining DH; Rajan E; Gostout CJ; Kraichely RE; Buttar NS; Schroeder KW; Kisiel JB; Larson MV; Sweetser SR; Sedlack RR; Sinicrope SN; Richmond E; Umar A; Della'Zanna G; Noaeill JS; Meyers JP; Foster NR
Cancer Prev Res (Phila); 2019 Nov; 12(11):821-830. PubMed ID: 31484660
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
9. DFMO: targeted risk reduction therapy for colorectal neoplasia.
Laukaitis CM; Gerner EW
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):495-506. PubMed ID: 22122766
[TBL] [Abstract][Full Text] [Related]
10. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
[TBL] [Abstract][Full Text] [Related]
11. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.
Zell JA; McLaren CE; Chen WP; Thompson PA; Gerner EW; Meyskens FL
J Natl Cancer Inst; 2010 Oct; 102(19):1513-6. PubMed ID: 20798393
[TBL] [Abstract][Full Text] [Related]
12. Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model.
Nicastro HL; Grubbs CJ; Margaret Juliana M; Bode AM; Kim MS; Lu Y; You M; Milne GL; Boring D; Steele VE; Lubet RA
Cancer Prev Res (Phila); 2014 Feb; 7(2):246-54. PubMed ID: 24346344
[TBL] [Abstract][Full Text] [Related]
13. Polyamines as mediators of APC-dependent intestinal carcinogenesis and cancer chemoprevention.
Rial NS; Meyskens FL; Gerner EW
Essays Biochem; 2009 Nov; 46():111-24. PubMed ID: 20095973
[TBL] [Abstract][Full Text] [Related]
14. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone.
Sporn MB; Hong WK
Cancer Prev Res (Phila); 2008 Jun; 1(1):9-11. PubMed ID: 19138930
[No Abstract] [Full Text] [Related]
15. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
16. Eflornithine for chemoprevention in the high-risk population of colorectal cancer: a systematic review and meta-analysis with trial sequential analysis.
Yang L; Wang Y; Hu S; Wang X
Front Oncol; 2023; 13():1281844. PubMed ID: 38033490
[TBL] [Abstract][Full Text] [Related]
17. Nonsteroidal anti-inflammatory drugs and aspirin for the prevention of colorectal adenomas and cancer: a systematic review.
Asano TK; McLeod RS
Dis Colon Rectum; 2004 May; 47(5):665-73. PubMed ID: 15054679
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
Grau MV; Sandler RS; McKeown-Eyssen G; Bresalier RS; Haile RW; Barry EL; Ahnen DJ; Gui J; Summers RW; Baron JA
J Natl Cancer Inst; 2009 Feb; 101(4):267-76. PubMed ID: 19211442
[TBL] [Abstract][Full Text] [Related]
19. Preventive effects of chemical drugs on recurrence of colorectal adenomas: systematic review and Bayesian network meta-analysis.
Tan S; Ou Y; Yang Y; Huang S; Chen S; Gao Q
Eur J Gastroenterol Hepatol; 2024 Jan; 36(1):62-75. PubMed ID: 37942763
[TBL] [Abstract][Full Text] [Related]
20. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
Cole BF; Logan RF; Halabi S; Benamouzig R; Sandler RS; Grainge MJ; Chaussade S; Baron JA
J Natl Cancer Inst; 2009 Feb; 101(4):256-66. PubMed ID: 19211452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
